![Tyson Foods Plant [Photo: Food Manufacturing]](https://southarkansassun.com/wp-content/uploads/2023/08/iStock_1185520857__1_.5e441daa51cca-600x337.jpg)
![Silverado Senior Living Management Inc. [Photo: Los Angeles Times]](https://southarkansassun.com/wp-content/uploads/2023/10/download-6-4-600x337.jpg)
![China's Wuhan Institute of Virology [Photo: Nature]](https://southarkansassun.com/wp-content/uploads/2023/09/d41586-021-01529-3_19239608-600x337.jpg)
The U.S. Food and Drug Administration (FDA) is investigating potential risks associated with widely used weight-loss drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound. The quarterly report highlights concerns including hair loss, aspiration, and suicidal ideation among users of GLP-1 receptor agonists (GLP-1 RA). While investigations continue, previous inquiries led to label updates or additional studies. Last year, the FDA explored intestinal obstructions linked to these medications, prompting revisions to Ozempic’s labeling. Drug manufacturers, Novo Nordisk and Eli Lilly, express commitment to safety. Through September, reports include 201 instances of suicide or suicidal thoughts and 422 cases of hair loss associated with semaglutide or tirzepatide.
Potential Risks Under Scrutiny
The FDA is intensifying scrutiny on GLP-1 RA weight-loss drugs, investigating cases of hair loss, aspiration, and suicidal ideation. Previous safety concerns prompted label updates, indicating the seriousness of ongoing assessments.
Novo Nordisk and Eli Lilly, manufacturers of Ozempic, Wegovy, Mounjaro, and Zepbound, affirm their commitment to user safety. FDA collaboration is underway to assess potential risks associated with GLP-1 RA medicines.
Reports through September reveal 201 cases of suicide or suicidal ideation and 422 instances of hair loss tied to semaglutide or tirzepatide, signaling the need for continued vigilance in monitoring the safety of these weight-loss medications.
Uncommon Dangers and Medical Community Response
An uncommon danger associated with these medications is aspiration, with 18 reported cases. The FDA’s vigilance is evident in ongoing assessments, with a case report highlighting a patient experiencing aspiration after starting semaglutide injections for weight loss.
In response to potential complications, the American Society of Anesthesiologists recommended patients cease using these weight-loss drugs before elective surgeries, emphasizing patient safety.
While the investigation unfolds, manufacturers stress the importance of proper use under healthcare professional guidance, aiming to balance the potential benefits of weight loss with vigilant monitoring for any emerging risks.
READ ALSO: Bridgeport School Superintendent Unveils Mental Health Initiative
